Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Merck's Net Income (Continuing Operations) for the
three
months ended in Jun. 2026 was CHF-1,069 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 was CHF2,558 Mil.
Merck (XSWX:MRK) Net Income (Continuing Operations) Explanation
Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.
Merck Net Income (Continuing Operations) Related Terms
Merck Net Income (Continuing Operations) Historical Data
* Premium members only.
The historical data trend for Merck's Net Income (Continuing Operations) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Merck Net Income (Continuing Operations) Calculation
Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.
Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF2,558 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Net Income (Continuing Operations) of CHF2,558 Mil mean?
Merck (XSWX:MRK) has a Net Income (Continuing Operations) of CHF2,558 Mil as of Jun. 2026. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Merck and its competitors.
Is Merck's Net Income (Continuing Operations) too high?
Merck's current Net Income (Continuing Operations) is CHF2,558 Mil. Overall, Merck has a GF Score™ of 70/100, reflecting its overall financial health beyond just this single metric.
How does Merck's Net Income (Continuing Operations) compare to AMGN and ABBV?
Merck's Net Income (Continuing Operations) of CHF2,558 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Income (Continuing Operations) for a Drug Manufacturers company?
A good Net Income (Continuing Operations) depends on the Drug Manufacturers industry context. However, Net Income (Continuing Operations) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Income (Continuing Operations) mean?
A high Net Income (Continuing Operations) can signal that a stock is expensive relative to its fundamentals. Net Income (Continuing operations) is the total net earnings from a company's continuing operations. View historical data on Merck and its competitors. Merck's current Net Income (Continuing Operations) is CHF2,558 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Merck stock overvalued right now?
Merck (XSWX:MRK) has a current Net Income (Continuing Operations) of CHF2,558 Mil. The stock's GF Value™ is CHF95.99, compared to a current price of CHF122.12 — trading 27.2% above its estimated fair value. The current Net Income (Continuing Operations) is CHF2,558 Mil. Merck's overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Income (Continuing Operations) calculated?
Net Income (Continuing Operations) is calculated from a company's financial statements. For Merck (XSWX:MRK), the current Net Income (Continuing Operations) is CHF2,558 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Merck (XSWX:MRK) Overvalued in 2026?
Based on GuruFocus' analysis, Merck stock appears to be overvalued.
The current stock price of CHF122.12 is trading 27.2% above its estimated GF Value™ of CHF95.99.
Key valuation signals for XSWX:MRK:
Net Income (Continuing Operations): CHF2,558 Mil
GF Value™: CHF95.99 vs. price of CHF122.12 (27.2% above fair value)
No single metric tells the full story. See the XSWX:MRK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
70GF Score
Get the complete analysis for XSWX:MRK
Net Income (Continuing Operations) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:MRK has been successfully added to your 
